David F. Hale

David F. Hale is President and CEO of CancerVax Corporation a
biotechnology company involved in the research, development,
manufacturing and marketing of immunotherapy products for the treatment
of cancer. Prior to CancerVax, Hale was President and CEO of Women First
HealthCare, from January 1998 to June 2000. Prior to Women First
HealthCare, Hale was President and CEO of Gensia Sicor, formerly Gensia,
Inc., from 1987 to 1997 and Chairman from 1991 to 1997. Prior to Gensia
Sicor, Hale was President and CEO of Hybritech Inc., a division of Eli
Lilly and Company, from 1986 to 1987. He jointed Hybritech as Senior
Vice President Marketing and Business Development, became Executive Vice
President and Chief Operating Officer in late 1982 and President in
1983. Prior to joining Hybritech, Hale was Vice President and General
Manager of BBL Microbiology Systems, division of Becton Dickinson & Co.,
and from January 1980 to February 1981 he was Vice President, Sales &
Marketing. From 1971 to 1980 he held various marketing management
positions with Ortho Pharmaceutical Corporation, a division of Johnson &
Johnson, including Director of Marketing and Director of Product
Management for Ortho Pharmaceutical Corporation. Hale serves on the
Board of Directors of Dura Pharmaceuticals, a company involved in
products to treat respiratory infections; LMA North America, a company
involved in products for use in anesthiology; Santarus, Inc., a company
involved in the development of products for GI disease; and Metabasis
Therapeutics, a biotechnology company. Hale also serves on the Board of
BIOCOM/San Diego (formerly the Biomedical Industry Council (BIC) of
which he was the founder). Hale also serves on the Board of Directors of
the University of California, San Diego Foundation, the San Diego
Economic Development Corporation, Children’s Hospital of San Diego, and
Francis W. Parker School. He is also a founder of UCSD’s CONNECT Program
in Technology and Entrepreneurship and was recently appointed to serve
on the Mayor’s Science and Technology Council.